A Phase 1/2 interventional study of B244 and Placebo in Acne Vulgaris, sponsored by AOBiome LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by AOBiome LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 241st largest by enrollment of the 353 interventional ones that give a count, is one of 25 that started in 2015, is one of 11 in phase 1/2, and was the 184th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 25 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 322 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 3 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.
After a screening visit and a one-week washout (if applicable), three sequential ascending doses of the study drug will be applied twice-daily (BID) for 14 days in three groups of subjects. Each group of subjects will be randomized to receive the planned doses of B244 or placebo BID
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of facial acne vulgaris defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 Dose 1 (dose level \[cells/mL\] 20,000,000,000)
Drug: B244 · Drug: Placebo
B244 Dose 2 (dose level \[cells/mL\] 40,000,000,000)
Drug: B244 · Drug: Placebo
B244 Dose 3 (dose level \[cells/mL\] 80,000,000,000)
Drug: B244 · Drug: Placebo
Placebo to Match B244
Drug: B244
10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
Safety (Number of Participants With Treatment Related Adverse Events)
Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses
Time frame: 4 weeks
Efficacy
Absolute Change from Baseline in Total Number of Lesions
Time frame: Baseline and 4 weeks
| Milestone | Dose I | Dose II | Dose III | Placebo |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 2 | 3 | 2 | 2 |
Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses
| Participants | Dose I | Dose II | Dose III | Placebo |
|---|---|---|---|---|
| Safety (Number of Participants With Treatment Related Adverse Events) | 4 | 1 | 2 | 2 |
Absolute Change from Baseline in Total Number of Lesions
| Lesions | Pooled Active Doses | Placebo |
|---|---|---|
| Efficacy | -9.6 ± 12.09 | -6.7 ± 10.66 |
Collected over Subjects were monitored for Adverse Events from Study Day 1 through Day 28 of the study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose I | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Dose II | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Dose III | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Event | Dose I | Dose II | Dose III | Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/9 | 0/9 | 0/9 | 0/9 |
| Application Site PainGeneral disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| HeadacheNervous system disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| MigraineNervous system disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| Urinary Tract infectionInfections and infestations | 1/9 | 0/9 | 0/9 | 0/9 |
| PyrexiaGeneral disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| VomitingGastrointestinal disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| Arthropod StingInjury, poisoning and procedural complications | 0/9 | 1/9 | 0/9 | 0/9 |
| Streptococcal InfectionInfections and infestations | 0/9 | 1/9 | 0/9 | 0/9 |
All subjects were adult men or women, between the ages of 18 and 45 years.
| Age, Continuous(years) | Dose I | Dose II | Dose III | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.4 ± 10.0 | 26 ± 8.2 | 29.2 ± 4.8 | 31.7 ± 10.1 | 29.1 ± 8.4 |
| Sex: Female, Male(Participants) | Dose I | Dose II | Dose III | Placebo | Total |
|---|---|---|---|---|---|
| Female | 7 | 5 | 7 | 9 | 28 |
| Male | 2 | 4 | 2 | 0 | 8 |
| Race (NIH/OMB)(Participants) | Dose I | Dose II | Dose III | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 3 | 2 | 7 |
| White | 3 | 2 | 5 | 4 | 14 |
| More than one race | 1 | 2 | 0 | 0 | 3 |
| Unknown or Not Reported | 3 | 3 | 1 | 2 | 9 |
Ran from Aug 2015 to primary completion in Mar 2016, 6 months.
Results were first posted in Apr 2017, 1 year 1 month after primary completion.
Of 13 phase 1/2 interventional studies under Acne Vulgaris, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC